The Subject Expert Committee (Sec) Of The Central Drugs Standard Control Organisation (Cdsco) Has Granted Permission To Sun Pharma Ltd To Conduct Phase Iii Clinical Trial For Its Antipsychotic Drug Pimavanserin In India.The Permission Was Granted In A Meeting Held By The New Drug Division Of Sec On January 18, In The Cdsco Headquarters In New Delhi. The Company Submitted A Revised Phase Iii Clinical Trial Protocol Before The Committee Following The Latter
